Saturday 17 October 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROS Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.66
0.44
−3.96%
Follow KROS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 19.10 | 28.50 | 24.38 | 27.02 | 15.33 | 9.12 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 88.80 | 75.99 | 68.29 | 59.96 | 73.00 | 22.55 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 23 | 35 | 60 | 105 | 136 | 169 | 78 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.43 | 0.00 | 0.34 | 0.00 | 0.00 | 0.02 | 3.13 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 10 | 10 | — | 20 | — | 0 | 4 | 244 | ||||
| Gross margin, % | — | — | 0.00 | 100.00 | 0.00 | 100.00 | 0.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | (1) | (12) | (46) | (57) | (105) | (153) | (187) | 92 | |||||
| EBT margin, % | — | — | (10.78) | (123.36) | 0.00 | (282.25) | 0.00 | (101,319.21) | (5,269.10) | 37.65 | |||||
| Net income | — | 0 | (1) | (12) | (45) | (59) | (105) | (153) | (187) | 87 | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.53 | 4.30 | 0.00 | 0.86 | 0.00 | 0.01 | 0.09 | 6.56 | ||||
| Earnings | — | — | (0.12) | (5.30) | (2.93) | (2.52) | (4.15) | (5.20) | (5.00) | 2.34 | |||||
| Cash flow | — | — | 0.37 | (6.87) | (2.38) | (2.66) | (2.78) | (4.23) | (4.30) | 2.89 | |||||
| Capex | — | — | 0.00 | (0.12) | (0.02) | (0.04) | (0.05) | (0.08) | (0.05) | (0.04) | |||||
| Free cash flow | — | — | 0.37 | (6.99) | (2.40) | (2.71) | (2.82) | (4.31) | (4.35) | 2.85 | |||||
| Book value | — | — | (0.38) | 0.21 | 16.88 | 10.42 | 10.99 | 11.28 | 15.27 | 8.14 | |||||
| Shares, m | — | — | 19 | 2 | 16 | 23 | 25 | 29 | 37 | 37 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 10.95 | ||||
| P/S | — | — | 4.99 | 4.99 | — | 54.39 | — | 62.72 | 166.94 | 3.11 | |||||
| P/B | — | — | 0.00 | 0.00 | — | 5.61 | — | 3.82 | 1.04 | 2.50 | |||||
| EV/Sales | — | — | (0.46) | (0.46) | — | 45.23 | — | 46.36 | 9.21 | 1.93 | |||||
| EV/FCF | — | — | 0.21 | 0.21 | — | (17.97) | — | (7.39) | (0.20) | 4.44 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | 7 | (16) | (37) | (62) | (70) | (125) | (161) | 108 | ||||
| Capex | — | — | 0 | 0 | 0 | (1) | (1) | (2) | (2) | (2) | |||||
| Free cash flow | — | — | 7 | (16) | (37) | (63) | (71) | (127) | (163) | 106 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 14 | 4 | 261 | 240 | 269 | 323 | 561 | 295 | ||||
| Total debt | — | — | 23 | 26 | 1 | 1 | 13 | — | — | — | |||||
| Net debt | — | — | 0 | (7) | (266) | (230) | (279) | (331) | (560) | (287) | |||||
| Shareholders’ equity | — | — | (7) | 0 | 262 | 243 | 277 | 332 | 572 | 303 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (17.12) | (73.69) | (32.35) | (22.39) | (37.25) | (45.21) | (38.01) | 18.24 | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (268.30) | 0.00 | (9,963.71) | (1,133.80) | 268.69 | |||||
| ROE | — | — | 17.62 | 106.17 | (37.45) | (23.27) | (40.21) | (50.19) | (41.46) | 19.90 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Mar 2026
Charts ten years each
Keros Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics, Inc. | $226.6M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SLGL Sol-Gel Technologies Ltd. | $224.9M | — (loss-making) | — (loss-making) | −96.58% (below 0%: shrinking) | n/m | −8.76% (below 0%: shrinking) | 100.00% | (704.23%) | Compare |
| GLSI Greenwich LifeSciences, Inc. | $224.9M | — (loss-making) | — | — | n/m | +13.14% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KROS Keros Therapeutics, Inc. | $220.1M | — (loss-making) | — (loss-making) | −99.83% (below 0%: shrinking) | n/m | +32.19% (above 0%: growing) | 100.00% | 0.00% | |
| PLX Protalix BioTherapeutics, Inc. | $217.5M | 10.9× | 10.2× | +27.07% (above 0%: growing) | +2,280.95% (above 0%: growing) | −94.09% (below 0%: shrinking) | 60.99% | 23.48% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $216.5M | — (loss-making) | — (loss-making) | +18.84% (above 0%: growing) | n/m | −23.90% (below 0%: shrinking) | 100.00% | (752.11%) | Compare |
| PYXS Pyxis Oncology, Inc. | $215.3M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $215.2M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $214.7M | — (loss-making) | — (loss-making) | +377.97% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| Median of peers | $217.0M | — | — | +22.96% | — | +3.71% | 100.00% | 0.00% |
Keros Therapeutics, Inc. (KROS) key facts
- Keros Therapeutics, Inc. (KROS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, KROS traded at $10.66, a market capitalization of $220.1 million.
- Return on equity was 19.9% and debt-to-equity 0.00.
- Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 13.47 (safe zone) for fiscal 2025.
Keros Therapeutics, Inc. (KROS) Latest News
No news at this impact. Lower the threshold for more.